Latest Advances in Lung Cancer Research

The study highlights that the timing of irAEs depends on the specific immunotherapy and recent treatment history.

New research separates the effects of smoking, environment, genetics, and healthcare access on lung cancer mortality, providing insights for better prevention strategies.

Phase III trial shows mobocertinib performs similarly to chemotherapy for EGFR exon 20 insertion lung cancer patients.

Early detection of incidental lung nodules can lead to timely treatment and improved survival rates for lung cancer patients.

New hope for small cell lung cancer patients as the first patient receives Peluntamig in a clinical trial. This experimental drug targets specific cancer growth pathways.

New blood test using ctDNA methylation biomarkers shows promise for early lung cancer detection, potentially improving treatment outcomes for patients.

New drug shrinks HER2-mutant lung cancer tumors in 73% of patients, offering hope for improved treatment options.

Final study results show selpercatinib achieves 83% response rate in treatment-naive RET fusion lung cancer patients with durable responses.

Comprehensive review examining molecular mechanisms of cancer invasion and metastasis, identifying potential therapeutic targets for preventing cancer spread.

Final clinical trial results demonstrate selpercatinib’s safety and efficacy in treating RET fusion-positive non-small cell lung cancer patients.

Increasing lung cancer cases in non-smokers highlight the need for research into causes and improved detection methods

UC Davis Health introduces cutting-edge CT imaging technology that detects smaller lung tumors with less radiation, improving early detection and treatment planning.